Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options.

Leveraging our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas.